Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GH Research PLC (GHRS)
USD26.55
-0.23 (-0.84%)
IE NASDAQ Healthcare Biotechnology
Address
28 Baggot Street Lower D02 NX43
Dublin, DU, IE
Dublin, DU, IE
CEO
Velichka Valcheva
Website
ghres.com
IPO
2021-06-25
CIK 1855129 ISIN IE000GID8VI0
Description
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.55
-0.23 (-0.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
265.2K
Beta
1.29
Float Shares
49.37M
Free Float %
72.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.69% | +0.38% | +16.63% | +33.77% | +51.70% | +68.43% | +82.82% | +93.40% | +11.12% | +11.12% | +11.12% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
26.55
Low
32.00
+20.6%
Consensus
36.50
+37.5%
Median
37.00
+39.4%
High
40.00
+50.7%
DCF (Unlevered)
4.04
-84.8%
DCF (Levered)
4.03
-84.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
33.00
+24.3%
|
| Last Year | 9 |
32.89
+23.9%
|
| All Time | 11 |
32.27
+21.6%
|
Quality scores
Altman Z-Score
73.55
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-5.3% Q1'26: -63.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,132.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.3% Q1'26: +6.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 9 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 7 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
50.65M
50.65M – 50.65M
|
3.23M
3.23M – 3.23M
-93.6% YoY
|
91.35M
91.35M – 91.35M
+2,729.5% YoY
|
345.91M
345.91M – 345.91M
+278.7% YoY
|
| EBITDA |
-38.60M
|
-60.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-38.91M
|
-60.68M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-38.96M
est: -42.41M (+8.1%)
|
-48.26M
est: -50.93M (+5.3%)
|
-92.57M
-115.73M – -61.23M
-81.7% YoY
|
-134.71M
-140.10M – -83.20M
-45.5% YoY
|
-164.85M
-218.91M – -93.04M
-22.4% YoY
|
-98.71M
-98.71M – -98.71M
+40.1% YoY
|
8.98M
8.98M – 8.98M
+109.1% YoY
|
| SGA |
15.00M
|
21.61M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.75
est: -0.81 (+7.4%)
|
-0.79
est: -0.84 (+6.4%)
|
-1.40
-1.90 – -1.00
-65.7% YoY
|
-1.95
-2.30 – -1.36
-39.6% YoY
|
-2.22
-3.59 – -1.52
-13.9% YoY
|
-1.62
-1.62 – -1.62
+27.2% YoY
|
0.15
0.15 – 0.15
+109.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
152.56M
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Florian Schonharting | 15.07M | 29.00% | 15.07M | — | 15.07M | — | IN | Denmark | 2022-02-09 | ↗ |
| 2 | BVF Inc. | 9.28M | 17.80% | — | — | — | 9.28M | CO | — | 2022-02-14 | ↗ |
| 3 | BVF Partners L.P. | 9.28M | 17.80% | — | — | — | 9.28M | IA, PN | — | 2022-02-14 | ↗ |
| 4 | Mark N. Lampert | 9.28M | 17.80% | — | — | — | 9.28M | IN | — | 2022-02-14 | ↗ |
| 5 | BVF GP Holdings LLC | 8.62M | 16.60% | — | — | — | 8.62M | OO | — | 2022-02-14 | ↗ |
| 6 | Theis Terwey | 6.42M | 12.30% | 6.42M | — | 6.42M | — | IN | Germany | 2022-02-09 | ↗ |
| 7 | Abigail P. Johnson | 5.09M | 9.79% | — | — | 5.09M | — | IN | United States of America | 2022-02-09 | ↗ |
| 8 | FMR LLC | 5.09M | 9.79% | 1.39M | — | 5.09M | — | HC | Delaware | 2022-02-09 | ↗ |
| 9 | BVF I GP LLC | 4.84M | 9.30% | — | — | — | 4.84M | OO | — | 2022-02-14 | ↗ |
| 10 | Biotechnology Value Fund, L.P. | 4.84M | 9.30% | — | — | — | 4.84M | PN | — | 2022-02-14 | ↗ |
| 11 | BVF II GP LLC | 3.77M | 7.30% | — | — | — | 3.77M | OO | — | 2022-02-14 | ↗ |
| 12 | Biotechnology Value Fund II, L.P. | 3.77M | 7.30% | — | — | — | 3.77M | PN | — | 2022-02-14 | ↗ |
| 13 | RTW Investments, LP | 3.33M | 6.40% | — | 3.33M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 14 | Roderick Wong, M.D. | 3.33M | 6.40% | — | 3.33M | — | — | HC, IN | United States | 2024-02-14 | ↗ |
| 15 | Lynx1 Capital Management LP | 2.99M | 5.80% | — | 2.99M | — | — | PN | Delaware | 2024-02-16 | ↗ |
| 16 | Weston Nichols | 2.99M | 5.80% | — | 2.99M | — | — | IN | Delaware | 2024-02-16 | ↗ |
| 17 | Peter Kolchinsky | 2.98M | 5.90% | — | 2.98M | — | — | HC, IN | Delaware | 2021-07-09 | ↗ |
| 18 | RA Capital Management, L.P. | 2.98M | 5.90% | — | 2.98M | — | — | IA, PN | Delaware | 2021-07-09 | ↗ |
| 19 | Rajeev Shah | 2.98M | 5.90% | — | 2.98M | — | — | HC, IN | Delaware | 2021-07-09 | ↗ |
| 20 | Koh, Bong | 2.82M | 5.40% | — | 2.82M | — | — | IN | United States | 2022-05-27 | ↗ |
| 21 | Shah, Nimish | 2.82M | 5.40% | — | 2.82M | — | — | IN | United States | 2022-05-27 | ↗ |
| 22 | VHCP Co-Investment Holdings II, LLC | 2.82M | 5.40% | — | 2.82M | — | — | OO | Delaware | 2022-05-27 | ↗ |
| 23 | VHCP Co-Investment Holdings III, LLC | 2.82M | 5.40% | — | 2.82M | — | — | OO | Delaware | 2022-05-27 | ↗ |
| 24 | VHCP Management EG, LLC | 2.82M | 5.40% | — | 2.82M | — | — | OO | Delaware | 2022-05-27 | ↗ |
| 25 | VHCP Management II, LLC | 2.82M | 5.40% | — | 2.82M | — | — | OO | Delaware | 2022-05-27 | ↗ |
| 26 | VHCP Management III, LLC | 2.82M | 5.40% | — | 2.82M | — | — | OO | Delaware | 2022-05-27 | ↗ |
| 27 | Venrock Healthcare Capital Partners EG, L.P. | 2.82M | 5.40% | — | 2.82M | — | — | PN | Delaware | 2022-05-27 | ↗ |
| 28 | Venrock Healthcare Capital Partners II, L.P. | 2.82M | 5.40% | — | 2.82M | — | — | PN | Delaware | 2022-05-27 | ↗ |
| 29 | Venrock Healthcare Capital Partners III, L.P. | 2.82M | 5.40% | — | 2.82M | — | — | PN | Delaware | 2022-05-27 | ↗ |
| 30 | RA Capital Healthcare Fund, L.P. | 2.67M | 5.30% | — | 2.67M | — | — | PN | Delaware | 2021-07-09 | ↗ |
| 31 | BVF Partners OS Ltd. | 649.1K | 1.30% | — | — | — | 649.1K | CO | — | 2022-02-14 | ↗ |
| 32 | Biotechnology Value Trading Fund OS LP | 649.1K | 1.30% | — | — | — | 649.1K | PN | — | 2022-02-14 | ↗ |
| 33 | Spike Loy | — | 0.00% | — | — | — | — | IN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-50 vs prev Q
New positions
2
Closed positions
47
Increased
6
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | LYNX1 CAPITAL MANAGEMENT LP | 10.41M +1.8M (+21.0%) | 132.16M +27.9M (+26.7%) | 16.78% +2.910 pp | 26.75% +5.522 pp | USD11.33 +12.1% | 11 qtrs — |
| 2 | BVF INC/IL | 8.83M +— (+0.0%) | 112.11M -14.1M (-11.2%) | 14.23% 0.000 pp | 3.77% -1.343 pp | USD20.01 -36.5% | 19 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 7.68M +— (+0.0%) | 97.49M -12.3M (-11.2%) | 12.38% 0.000 pp | 1.00% -0.354 pp | USD16.69 -23.9% | 19 qtrs — |
| 4 | RTW INVESTMENTS, LP | 5.93M +364.3K (+6.5%) | 75.36M -4.3M (-5.4%) | 9.57% +0.587 pp | 0.75% -0.227 pp | USD14.88 -14.7% | 19 qtrs — |
| 5 | FMR LLC | 5.14M -191.0K (-3.6%) | 65.23M -10.9M (-14.4%) | 8.28% -0.308 pp | 0.00% -0.001 pp | USD16.67 -23.8% | 19 qtrs — |
| 6 | AVORO CAPITAL ADVISORS LLC | 1.80M +1.8M (+100.0%) | 22.86M +22.9M (+100.0%) | 2.90% +2.902 pp | 0.22% +0.220 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 7 | CORMORANT ASSET MANAGEMENT, LP | 1.30M -616.4K (-32.2%) | 16.51M -10.9M (-39.8%) | 2.10% -0.994 pp | 0.76% -1.128 pp | USD14.19 -10.5% | 19 qtrs — |
| 8 | JEFFERIES FINANCIAL GROUP INC. | 712.3K +3.0K (+0.4%) | 9.05M -1.1M (-10.8%) | 1.15% +0.005 pp | 0.05% -0.002 pp | USD11.04 +15.0% | 4 qtrs — |
| 9 | VERITION FUND MANAGEMENT LLC | 673.7K -4.8K (-0.7%) | 8.56M -1.1M (-11.8%) | 1.09% -0.008 pp | 0.03% -0.006 pp | USD14.94 -15.0% | 19 qtrs — |
| 10 | 5AM VENTURE MANAGEMENT, LLC | 572.7K +— (+0.0%) | 7.27M -916.3K (-11.2%) | 0.92% +0.000 pp | 2.29% -0.713 pp | USD10.83 +17.3% | 11 qtrs — |
| 11 | BLACKROCK, INC. | 434.4K +376.5K (+650.8%) | 5.52M +4.7M (+566.8%) | 0.70% +0.607 pp | 0.00% +0.000 pp | USD12.13 +4.7% | 6 qtrs — |
| 12 | TROLUCE CAPITAL ADVISORS LLC | 373.2K +326.5K (+698.8%) | 4.74M +4.1M (+609.4%) | 0.60% +0.526 pp | 3.01% +2.913 pp | USD12.49 +1.7% | 4 qtrs — |
| 13 | UBS GROUP AG | 363.4K -148.1K (-29.0%) | 4.61M -2.7M (-36.9%) | 0.59% -0.239 pp | 0.00% 0.000 pp | USD11.22 +13.2% | 8 qtrs — |
| 14 | — | 315.0K +315.0K (+100.0%) | 4.00M +4.0M (+100.0%) | 0.51% +0.508 pp | 1.70% +1.695 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 15 | MILLENNIUM MANAGEMENT LLC | 295.9K -567.7K (-65.7%) | 3.76M -8.6M (-69.6%) | 0.48% -0.915 pp | 0.00% -0.004 pp | USD13.80 -8.0% | 5 qtrs — |
| 16 | CENTERBOOK PARTNERS LP | 283.4K +117.3K (+70.6%) | 3.60M +1.2M (+51.5%) | 0.46% +0.189 pp | 0.18% +0.059 pp | USD13.64 -6.9% | 2 qtrs — |
| 17 | MARSHALL WACE, LLP | 240.8K +71.3K (+42.0%) | 3.06M +633.9K (+26.2%) | 0.39% +0.115 pp | 0.00% +0.000 pp | USD13.83 -8.2% | 2 qtrs — |
| 18 | HIGHVISTA STRATEGIES LLC | 240.5K -1.4K (-0.6%) | 3.05M -404.4K (-11.7%) | 0.39% -0.002 pp | 0.79% -0.061 pp | USD13.84 -8.2% | 3 qtrs — |
| 19 | ALYESKA INVESTMENT GROUP, L.P. | 205.0K +— (+0.0%) | 2.60M -328.0K (-11.2%) | 0.33% +0.000 pp | 0.01% -0.002 pp | USD11.03 +15.1% | 4 qtrs — |
| 20 | BOOTHBAY FUND MANAGEMENT, LLC | 112.2K +28.6K (+34.3%) | 1.42M +230.0K (+19.2%) | 0.18% +0.046 pp | 0.02% +0.004 pp | USD13.49 -5.9% | 4 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 81.0K +69.9K (+631.3%) | 1.03M +870.1K (+549.4%) | 0.13% +0.113 pp | 0.00% +0.000 pp | USD12.92 -1.7% | 2 qtrs — |
| 22 | ADVISORSHARES INVESTMENTS LLC | 67.1K +13.1K (+24.3%) | 852.3K +80.3K (+10.4%) | 0.11% +0.021 pp | 0.14% +0.016 pp | USD12.28 +3.4% | 18 qtrs — |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 66.6K +52.3K (+365.7%) | 845.8K +641.3K (+313.6%) | 0.11% +0.084 pp | 0.00% +0.000 pp | USD13.04 -2.6% | 2 qtrs — |
| 24 | TREXQUANT INVESTMENT LP | 54.8K +54.8K (+100.0%) | 695.7K +695.7K (+100.0%) | 0.09% +0.088 pp | 0.01% +0.006 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 25 | MORGAN STANLEY | 51.4K +47.2K (+1,111.8%) | 652.8K +592.2K (+976.2%) | 0.08% +0.076 pp | 0.00% +0.000 pp | USD13.14 -3.3% | 19 qtrs — |
| 26 | JANE STREET GROUP, LLC | 50.0K +27.0K (+117.4%) | 635.1K +306.1K (+93.1%) | 0.08% +0.044 pp | 0.00% +0.000 pp | USD13.44 -5.5% | 2 qtrs — |
| 27 | BIT CAPITAL GMBH | 50.0K +50.0K (+100.0%) | 635.0K +635.0K (+100.0%) | 0.08% +0.081 pp | 0.02% +0.023 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 28 | XTX TOPCO LTD | 44.4K +44.4K (+100.0%) | 564.5K +564.5K (+100.0%) | 0.07% +0.072 pp | 0.01% +0.015 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 29 | GEODE CAPITAL MANAGEMENT, LLC | 35.6K +— (+0.0%) | 452.7K -57.0K (-11.2%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD17.34 -26.8% | 18 qtrs — |
| 30 | NORTHERN TRUST CORP | 32.8K -145.0 (-0.4%) | 416.9K -54.6K (-11.6%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD6.76 +87.9% | 6 qtrs — |
| 31 | CITADEL ADVISORS LLC | 26.3K -68.1K (-72.2%) | 333.5K -1.0M (-75.3%) | 0.04% -0.110 pp | 0.00% 0.000 pp | USD14.30 -11.2% | 19 qtrs — |
| 32 | VIRTUS INVESTMENT ADVISERS, INC. | 20.4K +11.5K (+130.1%) | 259.2K +132.4K (+104.4%) | 0.03% +0.019 pp | 0.07% +0.034 pp | USD12.64 +0.5% | 3 qtrs — |
| 33 | JPMORGAN CHASE & CO | 18.9K +5.0K (+35.8%) | 239.8K +41.0K (+20.6%) | 0.03% +0.008 pp | 0.00% +0.000 pp | USD13.15 -3.4% | 3 qtrs — |
| 34 | GSA CAPITAL PARTNERS LLP | 18.6K +18.6K (+100.0%) | 236.0K +236.0K (+100.0%) | 0.03% +0.030 pp | 0.02% +0.020 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 35 | HRT FINANCIAL LP | 15.9K +15.9K (+100.0%) | 202.0K +202.0K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.001 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 36 | HIGHTOWER ADVISORS, LLC | 15.6K -500.0 (-3.1%) | 198.1K -32.1K (-13.9%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD12.19 +4.2% | 3 qtrs — |
| 37 | STATE STREET CORP | 10.8K -171.0 (-1.6%) | 137.4K -19.8K (-12.6%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD14.30 -11.2% | 2 qtrs — |
| 38 | LION POINT CAPITAL, LP | 10.2K +10.2K (+100.0%) | 129.5K +129.5K (+100.0%) | 0.02% +0.016 pp | 0.67% +0.670 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 39 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.1K +10.1K (+100.0%) | 128.4K +128.4K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.010 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 10.0K -100.0 (-1.0%) | 127.3K -9.4K (-6.9%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD11.08 +14.6% | 5 qtrs — |
| 41 | BANK OF AMERICA CORP /DE/ | 4.5K +4.2K (+1,518.2%) | 56.5K +52.6K (+1,337.3%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD12.54 +1.3% | 13 qtrs — |
| 42 | CITIGROUP INC | 4.4K +4.4K (+14,106.5%) | 55.9K +55.5K (+12,525.5%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD12.71 -0.1% | 2 qtrs — |
| 43 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.0K +3.0K (+100.0%) | 38.3K +38.3K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 44 | BARCLAYS PLC | 2.1K -3.9K (-64.6%) | 26.9K -13.1K (-32.8%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD14.30 -11.2% | 2 qtrs — |
| 45 | ROYAL BANK OF CANADA | 1.8K +52.0 (+3.0%) | 23.0K -2.0K (-8.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.07 +14.7% | 15 qtrs — |
| 46 | BNP PARIBAS ARBITRAGE, SNC | 1.3K -4.9K (-78.4%) | 17.0K -71.7K (-80.9%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD10.26 +23.8% | 5 qtrs — |
| 47 | WELLS FARGO & COMPANY/MN | 1.3K +— (+0.0%) | 15.9K -2.0K (-11.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.08 +14.6% | 8 qtrs — |
| 48 | GF FUND MANAGEMENT CO. LTD. | 1.2K +1.2K (+100.0%) | 15.5K +15.5K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 49 | TOWER RESEARCH CAPITAL LLC (TRC) | 770.00 +770.0 (+100.0%) | 9.8K +9.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 50 | GLOBAL RETIREMENT PARTNERS, LLC | 400.00 -400.0 (-50.0%) | 5.1K -6.4K (-55.6%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD14.01 -9.4% | 3 qtrs — |
| 51 | DAIWA SECURITIES GROUP INC. | 207.00 +207.0 (+100.0%) | 3.0K +3.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 52 | SIMPLEX TRADING, LLC | 48.00 -4.2K (-98.9%) | 609.00 -59.4K (-99.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD14.29 -11.1% | 2 qtrs — |
| 53 | SBI SECURITIES CO., LTD. | 20.00 +20.0 (+100.0%) | 254.00 +254.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.70 +0.0% | 1 qtrs NEW |
| 54 | GROUP ONE TRADING, L.P. | — -100.0 (-100.0%) | — -1.4K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 55 | POINT72 ASSET MANAGEMENT, L.P. | — -77.0K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.124 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 56 | SQUAREPOINT OPS LLC | — -36.1K (-100.0%) | — -516.3K (-100.0%) | 0.00% -0.058 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 57 | DEEP TRACK CAPITAL, LP | — -1.3M (-100.0%) | — -17.9M (-100.0%) | 0.00% -2.015 pp | 0.00% -0.499 pp | USD— | 4 qtrs SOLD |
| 58 | STEMPOINT CAPITAL LP | — -545.3K (-100.0%) | — -7.8M (-100.0%) | 0.00% -0.879 pp | 0.00% -1.562 pp | USD— | 3 qtrs SOLD |
| 59 | FARTHER FINANCE ADVISORS, LLC | — -200.0 (-100.0%) | — -2.9K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 60 | TANG CAPITAL MANAGEMENT LLC | — -24.0K (-100.0%) | — -343.6K (-100.0%) | 0.00% -0.039 pp | 0.00% -0.013 pp | USD— | 2 qtrs SOLD |
| 61 | MAN GROUP PLC | — -22.1K (-100.0%) | — -315.5K (-100.0%) | 0.00% -0.036 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF PSIL | 4.26% | 1.89M | 1.84% |
| 2 | iShares MSCI Ireland ETF EIRL | 1.88% | 1.40M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.77% | 444.7K | 0.65% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.13% | 1.40M | 0.35% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.13% | 93.9K | 0.35% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.13% | 578.8K | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.13% | 93.4K | 0.19% |
| 8 | iShares Biotechnology ETF IBB | 0.10% | 9.34M | 0.44% |
| 9 | ProShares Ultra Nasdaq Biotechnology BIB | 0.07% | 60.7K | 1.19% |
| 10 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 296.8K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Schonharting Florian | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 14,824,419 | D | ↗ |
| 2026-03-18 | Valcheva Velichka | Officer | — | — | Share Options (Right to Buy) | 50,000 | 10.83 | 541.5K | 0 | D | ↗ |
| 2026-03-18 | Ryan Julie | Officer | — | — | Share Options (Right to Buy) | 30,000 | 0.03 | 750.00 | 0 | D | ↗ |
| 2026-03-18 | Moore Duncan | Director | — | — | Share Options (Right to Buy) | 4,667 | 0.03 | 116.68 | 0 | D | ↗ |
| 2026-03-18 | Hanley Dermot John | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 2,432 | D | ↗ |
| 2026-03-18 | Halle Magnus Clemensen | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 118,354 | D | ↗ |
| 2026-03-18 | Forer Michael | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 45,509 | D | ↗ |
| 2026-03-18 | Cameron Aaron Luke | Officer | — | — | Share Options (Right to Buy) | 33,211 | 21.32 | 708.1K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
68.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aaron Cameron | Chief Operating Officer | — | male |
| Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board | — | male |
| Julie Ryan | Vice President of Finance | — | female |
| Magnus Halle | Co-Founder & MD of Ireland | — | male |
| Velichka Valcheva | Chief Executive Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GHRS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
